Background: a significant proportion of octogenarian patients with atrial fibrillation (AF) undergo percutaneous coronary intervention (PCI) with stenting. Dual antiplatelet therapy is recommended in these patients, requiring a period of triple therapy with dual antiplatelet agent plus oral anticoagulation (OAC). Concerns remain regarding the appropriateness of OAC in octogenarians. Methods: we reviewed 604 patients (15.7% ≥80 years) with AF undergoing PCI. Clinical follow-up was performed, recording any bleeding episode, thrombo-embolism and major adverse cardiac events (MACE = death, acute myocardial infarction and/or revascularisation of target lesion). We compared octogenarian patients in relation to treatment with OAC at discharge. A secondary aim was to compare octogenarian patients with non-octogenarian patients in terms of their clinical and demographic characteristics, management and clinical outcome. Results: among the 604 patients, 95(15.7%) were aged ≥80 years. Octogenarians had a higher median CHADS2 score (2.78 versus 2.01; P < 0.001) and HAS-BLED score (3.05 versus 2.84; P = 0.028). After a follow-up of 17 ± 14 months, allcause death occurred in 33%, MACE in 44%, and major bleeding in 21%. OAC was associated with less MACE (28.9 versus 58.3%; P = 0.012) and a similar rate of major bleeding. On multivariable analysis, non-use of OAC at discharge was associated with increased MACE (OR = 4.3; 95% CI = 1.3-14.6; P = 0.02). Conclusion: octogenarian AF patients undergoing PCI/stenting have a high mortality rate and MACE, which can be reduced by means of OAC therapy.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the general population, and its prevalence increases with age, occurring in 5-15% of the cases at 80 years old [1] [2] [3] [4] [5] . In patients with non-valvular AF, anticoagulation with coumarins is recommended in patients with a CHADS 2 score of ≥1 to reduce the risk of stroke and thrombo-embolic events [6] . Currently, octogenarian patients are increasingly undergoing percutaneous coronary intervention (PCI) when they are admitted with an acute coronary syndrome (ACS).
Following presentation with an ACS or coronary artery stent deployment, dual antiplatelet therapy with aspirin plus clopidogrel is advised [7, 8] , and if concomitant AF is present, oral anticoagulation (OAC) is also prescribed with antiplatelet therapy [9, 10] . The duration of triple therapy varies from 1 to 6 months depending on the type of stent, clinical context or indication for PCI and the bleeding risk. There is also the advice to avoid drug-eluting stents (DES) in order to reduce the duration of triple therapy and to subsequently continue with OAC plus one antiplatelet drug or coumarins alone [9, 10] .
Whether these guidelines can be strictly applied to very elderly population is unclear, given that octogenarian patients are a very high-risk group with a high prevalence of co-morbidities and they are also systematically excluded from randomised trials. Indeed, there is a lack of information about whether the risk-benefit ratio is maintained in this group of patients despite the increase in bleeding risk and co-morbidities, and which the most appropriate antithrombotic therapy regime.
In the present study, our aim was to determine the benefits and risks of using OAC in octogenarian patients with AF undergoing PCI/stenting. Our secondary aim was to compare the possible differences in the management and outcomes between these patients and non-octogenarian patients.
Methods
We conducted a retrospective two-centre registry analysis based on a search of our computerised PCI/stenting database of those patients diagnosed with AF who underwent PCI with at least 1 stent implanted over a 6-year period ( January 2002 to December 2007). Patients with a preexisting diagnosis of permanent, persistent or paroxysmal AF and those who developed new onset AF during their current admission were included in the analysis. All of the outcome data were collected post hoc. Patients who met these requirements were classified into two groups, as follows: (i) octogenarians (age ≥80 years old) and (ii) nonoctogenarians (<80 years old). Their clinical and demographic characteristics as well as their stroke risk factors and antithrombotic therapy use before PCI and at discharge were recorded.
The patients' risk of suffering a stroke was assessed according to the CHADS 2 score which assigns 1 point each for the presence of congestive heart failure, hypertension, age 75 years or older, and diabetes mellitus and by assigning 2 points for a history of stroke or transient ischaemic attack [11] . Their bleeding risk was evaluated using the HAS-BLED score (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65), drugs/alcohol concomitantly) [12] .
We performed a clinical follow-up and recorded all bleeding episodes, thrombo-embolism and MACE (death, acute myocardial infarction and target vessel revascularisation). Individual patient management decisions, such as the type of revascularisation performed or the type of stent implanted, were made by the responsible cardiologist, who also deciding the regimen of oral anticoagulation and/or antiplatelet drugs at discharge on the basis of the type of AF, stroke/thrombo-embolic risk factors, comorbidities, revascularisation procedure, and the type of stent used.
When discharged, patients were followed up as part of the usual routine of each centre. Telephone monitoring was also conducted to confirm the antithrombotic therapy regimen was being followed after discharge, as well as to ascertain any episodes of bleeding, stroke/thrombo-embolism and/or MACE. Clinical records of patients with hospital readmissions and/or outpatient clinic interviews were also reviewed for further information to validate our registry database.
Endpoint definitions
For the follow-up analysis, the primary endpoint was defined as the occurrence of MACE episodes, which included death, MI or target vessel revascularisation. A secondary safety endpoint was major adverse events (MAE), which included the occurrence of any MACE, major bleeding complications and/or stroke during the follow-up period. Myocardial infarction was defined as either the development of pathological Q-waves in at least two contiguous leads with a high creatine kinase-MB fraction level or, in the absence of pathological Q-waves, an increase in creatine kinase-MB levels to more than twice upper limit of normal. Major bleeding was defined as the decrease in the blood haemoglobin level of >5.0 g/dl (including the period around the coronary interventional procedure), the need to transfuse two or more units of blood, the need to perform corrective surgery, the occurrence of an intracranial or retroperitoneal haemorrhage, or any combination of these events [13] .
Statistical analysis
Continuous variables were tested for normal distribution by the Kolmogorov-Smirnov test. The normal distributed continuous variables are shown as mean ± SD, and those non-parametrically distributed are shown as median (interquartile range). Discrete variables are presented as frequencies ( percentages). The comparison of discrete variables was performed by the Chi-square test or (when the 2 × 2 table had <5 patients) the Fisher test. Comparisons of the groups for continuous variables were performed by unpaired t-test for independent samples that were parametrically distributed; for non-parametric variables by the MannWhitney U test was used. Survival analyses were initially conducted using a Kaplan-Meier analysis and compared by means of the log-rank test. Secondly, we performed a stepwise Cox proportional hazard model analysis, considering the presence of any event as an endpoint and introducing influencing variables such as the type of AF, different cardiovascular risk factors (e.g. hypertension, diabetes, heart failure etc.), use of DES, diameter and total length of stent and antithrombotic therapy at discharge. In the multivariate model, those variables that had a P-value <0.15 in the univariate analysis when comparing patients with and without oral anticoagulation at discharge were also included. All P-values were two-sided, and a P-value of <0.05 was considered statistically significant.
Results
From the cohort of 604 patients with AF undergoing PCI with stenting, 95 (15.7%) were age ≥80 years old (57.9% men, mean age 83 ± 3 years) and 509 (84.3%) were age <80 years old (74.5% men, mean age 70 ± 7 years) ( Table 1 ). The median value of the CHADS 2 score was higher in the group of octogenarian patients (2.78 versus 2.01; P < 0.001) as was the HAS-BLED score (3.05 versus 2.84; P = 0.028).
The most frequent indication for a catheterisation procedure in both octogenarian and non-octogenarian patients was an acute NSTEMI (67.9 versus 60.2%; P = 0.223) or an acute STEMI (26.2 versus 21.9%; P = 0.395). Catheterisation for stable angina was less common in octogenarian patients (4.8 versus 17.1%; P = 0.003). Radial vascular access was less used in octogenarian patients than in the non-octogenarians (5.8 versus 16.1%; P = 0.008). Coronary disease was more severe in octogenarian patients, with more multivessel disease than in non-octogenarian patients (69.5 versus 52.7%; P = 0.002). Fewer octogenarian patients had a complete revascularisation in comparison with a 64.4% of non-octogenarian ones (50.5 versus 64.4%; P = 0.011).
Antithrombotic drug regimen at discharge
In the octogenarian group, triple therapy (OAC, aspirin and clopidogrel) was prescribed in 26 patients (34.7%), with 52.9% receiving OAC at discharge. Octogenarian patients with permanent AF were discharged on OAC more frequently than patients with paroxysmal AF (65 versus 24%, P = 0.003). OAC was also more commonly used in diabetes mellitus (71 versus 43%, P = 0.014), and in those who were previously anticoagulated (73 versus 41%, P = 0.018).
Follow-up analysis
Complete follow-up was achieved in 95.9% of the cohort (median 17 ± 14 months). The incidence of MACE in octogenarians was 44.2%, with thrombo-embolic events in 12.6%, all-cause mortality in 33.3% and major bleeding in 20.0% of patients. The MAE rate was observed in 48.8% of octogenarian patients.
In the non-octogenarian group, the incidence of adverse events was lower, as follows: MACE (26.0 versus P = 0.001) and all-cause mortality (19.3 versus 33.3%; P = 0.006). The percentage of major bleedings was significantly less in non-octogenarian patients (10.9 versus 20%; P = 0.039), but minor bleedings were similar (10.4 versus 13.4%; P = 0.810). See Table 2 .
Octogenarian patients who were taking OAC at discharge had lower MACE events (28.9 versus 58.3%, P < 0.01) and a lower all-cause mortality rate at the followup (22.2 versus 44.4%, P = 0.05) compared with those discharged without OAC (Table 3 ; Figure 1a and b). For major bleeding, there were no differences related to OAC use at discharge (20.9 versus 21.2%) (Figure 1c) .
On univariate analysis, the only variable significantly associated with an increase in MACE in the octogenarian patients was the use of OAC at discharge (P = 0.012). The multivariate Cox-regression analysis found that the non-use of OAC was the only variable associated with a significant increase in MACE (OR = 4.3; 95 CI = 1.3-14.6; P = 0.02) with anon-significanttrendtoincreasedall-causedeath(Table4).
In the non-octogenarian group, the results were consistent whereby patients with OAC at discharge had significantly lower MACE events (20.1 versus 32.1%, P = 0.004) and a lower all-cause mortality rate (14.6 versus 23.6%, P = 0.015) compared with those without OAC.
Discussion
In this study, we show that octogenarian patients with AF who undergo a PCI with stenting are a high-risk group. These patients have a high risk of MACE, embolism, mortality and bleeding risk, can be reduced by OAC at hospital discharge.
Although it is recognised that octogenarian patients who present with a NSTEMI are at high risk [14] , the presence of AF in them may further increase their risk even more, worsening their already bad prognosis and making management even more difficult. Based on current guidelines, these patients have a significant risk of thrombo-embolism with a high CHADS 2 score and unsurprisingly, they present have high rates of MACE, embolism and mortality, and a higher rate of major bleeding.
Current guidelines [15] and consensus documents [9, 10] recommend the use of OAC in these AF patients after the PCI because of its favourable risk-benefit ratio, except in the case of contraindication or a considerable risk of bleeding. However, there are lack of data in elderly patients, and no prospective randomised trials on OAC in such patients to guide optimal management. The available information comes largely from registries, where octogenarians represent only a minority of patients and as far as we are aware, no specific analyses have yet been reported in these patients.
As AF prevalence increases with age, octogenarian patients represent a significant proportion of patients with AF (estimated as a 35-39% of all AF patients [2] [3] [4] [5] ), with a prevalence of this condition being 5-15% [16] . Thus, our study provides valuable information about clinical characteristics, clinical outcome and prognosis in a group of elderly patients with AF undergoing PCI.
The results of the present study confirm the recommendations of AF ESC guidelines in these high-risk patients, especially since 'non-use of OAC' was the only variable associated with an increase in MACE, and patients with coumarins presented a better free survival mortality and free survival of MACE.
Considering that anticoagulation is the most important determinant of mortality and MACE, and that it can improve the prognosis in these patients, all our strategies should be directed to reduce their bleeding risk (the major reason for not prescribing OAC at discharge). Previous studies have shown an increase in the risk of bleeding with the triple therapy in patients with AF undergoing PCI [17] [18] [19] [20] [21] . However, in this registry as well as in previous studies [22] , this risk is definitely outweighed by the major reduction in MACE and mortality in these patients by OAC use. Some strategies have been recommended in order to reduce bleeding risk in these patients [9] . The most important is to avoid the use of DES [23] to minimise the duration of triple therapy from 3 to 6 months to 1 month, and replace then with OAC plus one antiplatelet drug. Other important strategies are the use of radial vascular access instead of femoral access to reduce access site bleeding events, a strict control of the anticoagulation regimen to maintain an INR between 2.0 and 2.5 [24] and the use of gastric protection during the antithrombotic combination regimen.
Limitations
This study is based on a retrospective registry analysis, where the antithrombotic therapy regimen and the indication for OAC were non-randomised, but decided by the clinician. Thus, selection bias could influence the outcomes if patients with comorbidities were less likely to be selected for OAC or if patients with paroxysmal AF were less treated with OAC than those with a permanent of persistent AF due to an erroneously perceived lower risk of stroke [25, 26] . Another potential limitation of the study is the modest sample size, with important differences in the number of patients of each age-group, given that octogenarians were a minority of the total group.
In conclusion, octogenarian patients with AF undergoing PCI with stenting are a very high-risk group with a bad prognosis. OAC at discharge can significantly reduce the high rate of events in these patients.
Key points
• Octogenarian patients with AF undergoing PCI with stenting are a very high-risk group with a bad prognosis.
• Despite an increase in the bleeding risk, oral anticoagulation at discharge can significantly reduce the high rate of events in these patients with a favourable risk-benefit ratio.
• Some strategies have been recommended in order to reduce bleeding risk in these patients, like the use of bare metal stents and radial vascular access, a strict control of the anticoagulation regimen and the use of gastric protection. 
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